- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
B7-H3 Antibody B7H3/4313 / CD276 Mouse Monoclonal Antibody recognizes B7-H3, a type I transmembrane glycoprotein encoded by the CD276 gene and belonging to the B7 family of immunoregulatory proteins. B7-H3 contains extracellular immunoglobulin-like domains, a transmembrane segment, and a short cytoplasmic tail. Two-domain and four-domain forms have been described, with the four-domain form predominating in humans. Extensive glycosylation contributes to the protein's apparent molecular weight and may influence its stability and interactions at the cell surface.
B7 family proteins participate in the regulation of immune responses through interactions with receptors expressed by lymphocytes and other immune cells. B7-H3 was initially characterized as a costimulatory molecule capable of enhancing T-cell proliferation and interferon-gamma production. Subsequent investigations identified inhibitory effects on T-cell activation and cytokine secretion in certain experimental settings. These findings suggest that CD276 has context-dependent immunoregulatory functions. Although several potential binding partners have been proposed, its principal physiological receptor and the mechanisms governing its contrasting immune effects remain incompletely established.
CD276 has attracted considerable attention in cancer biology because elevated expression has been reported in numerous malignancies, including prostate, breast, ovarian, lung, and colorectal cancers. Expression may occur in malignant epithelial cells as well as tumor-associated stromal and vascular compartments. In several cancer types, increased B7-H3 abundance has been associated with aggressive pathological characteristics, metastatic progression, and unfavorable clinical outcomes. However, the strength and significance of these associations vary according to tumor type and experimental context.
Beyond its potential effects on immune surveillance, B7-H3 has been implicated in cellular migration, invasion, metabolic adaptation, and resistance to stress. Experimental studies suggest that CD276 may influence tumor-associated signaling pathways and interactions within the tumor microenvironment. These functions remain under investigation, and their molecular mechanisms have not been fully resolved.
The distribution of B7-H3 in malignant tissues has encouraged development of investigational therapeutic approaches, including monoclonal antibodies, antibody-drug conjugates, and engineered cellular therapies. B7-H3 Antibody B7H3/4313 provides a means of examining this tumor-associated glycoprotein and investigating its relationship to immune regulation, malignant progression, and cellular interactions within the tumor microenvironment.
For additional characterization of this tumor-associated immunoregulatory protein, see our CD276 Antibody B7H3/4345, a mouse monoclonal antibody supported by immunohistochemistry, western blot, and human protein microarray specificity data.
Optimal dilution of the B7-H3 Antibody B7H3/4313 / CD276 Mouse Monoclonal Antibody should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 100-300) from the human protein was used as the immunogen for the B7-H3 antibody.
Aliquot the B7-H3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
CD276 antibody, B7 homolog 3 antibody, B7 homologue 3 antibody, B7RP-2 antibody, B7H3 antibody, CD276 protein antibody, B7-H3 monoclonal antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.